The DOI matches its Crossref record; 28 of the 31 references it cites were found in a registry or an index.
Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes
Abstract
AIM: Metformin therapy reduces microvascular complications in Type 2 diabetes; questions remain, however, regarding its impact on macrovascular events. This study examined metformin use in relation to risk of cardiovascular-related hospitalization and mortality. METHODS: We conducted a retrospective cohort analysis, using Saskatchewan Health administrative databases to identify new users of oral antidiabetic drugs. Subject groups were defined by medication use during 1991-1999: sulphonylurea monotherapy, metformin monotherapy, or combination therapy. Deaths and non-fatal hospitalizations recorded during the study period were identified as cardiovascular-related from ICD-9 codes. The main outcome was a composite of first non-fatal hospitalization or death. Standard multivariate techniques, including propensity scores, were used to adjust for potential confounding. Multivariate Cox proportional hazard models were used to examine the relationship between metformin use and the composite endpoint. RESULTS: Metformin monotherapy was associated with a lower risk of the composite endpoint (adjusted hazard ratio 0.81; 95% confidence interval 0.68, 0.97) compared with sulphonylurea monotherapy. Combination therapy with meformin and a sulphonylurea was associated with lower mortality, but had similar hospitalization rates, to sulphonylurea monotherapy. CONCLUSIONS: Metformin monotherapy was associated with a lower risk of cardiovascular-related morbidity and mortality, and combination metformin and sulphonylurea therapy was associated with a reduced risk of fatal cardiovascular events, when compared with sulphonylurea monotherapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similarly, Johnson et al. accessed the Saskatchewan Health Administrative databases for a retrospective study and also reported reduced cardiovascular morbidity and mortality benefits of metformin monotherapy versus sulfonylurea monotherapy (31).”
From A Critical Review of the Evidence That Metformin Is a Putative Anti-Aging Drug That Enhances Healthspan and Extends Lifespan (2021) · cites this paper as [31]
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Randomized, Controlled Trials, Observational Studies, and the Hierarchy of Research Designs
Concato, J., Shah, N., & Horwitz, R. I. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006223422507 · Cited by 3,563
Estimating Causal Effects from Large Data Sets Using Propensity Scores
Rubin, D. V. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-127-8_part_2-199710151-00064 · Cited by 3,104
Reducing Bias in Observational Studies Using Subclassification on the Propensity Score
Rosenbaum, P. R., & Rubin, D. B. (1984) · Journal of the American Statistical Association · doi:10.1080/01621459.1984.10478078 · Cited by 3,082
Efficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes Mellitus
DeFronzo, R. A., & Goodman, A. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330902 · Cited by 1,368
Invited commentary: propensity scores.
Joffe, M., & Rosenbaum, P. (1999) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a010011 · Cited by 1,117
Research works printed but not linked: 1
- Tsuyuki RT, 1999, Nitroglycerin as an indicator for the presence of coronary heart disease, Can Pharmaceut J, 132, 32
Cited by
Sorted by citations
Items 101–161 of 161
Eskin, M., Simpson, S. H., & Eurich, D. T. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2018.12.001 · Cited by 12
Reduced Mortality Associated With the Use of Metformin Among Patients With Autoimmune Diseases
Lin, C., Wu, C., Hsu, C.-Y., Chen, T., Lin, M., Lin, Y., & Su, Y. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.641635 · Cited by 11
Chen, J., Wang, L., Tian, G. G., Wang, X., Li, X., & Wu, J. (2023) · Stem Cell Reviews and Reports · doi:10.1007/s12015-023-10575-5 · Cited by 10
Type 2 diabetes, metformin and lactic acidosis—defining the risk and promoting safe practice
Senior, P. A. (2011) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03469.x · Cited by 10
Metformin ameliorates valve interstitial cell calcification by promoting autophagic flux
Phadwal, K., Tan, X., Koo, E. W. Y., Zhu, D., & MacRae, V. E. (2023) · Scientific Reports · doi:10.1038/s41598-023-47774-6 · Cited by 11
Shin, S., & Kim, H. (2016) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s105285 · Cited by 9
Insulin plus metformin for T2DM—are there benefits?
Bailey, C. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.106 · Cited by 9
Schöndorf, T., Karagiannis, E., Posseldt, R. E. K., Forst, T. M., & Pfützner, A. (2009) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2008.0108 · Cited by 9
Johnson, J. A., Simpson, S. H., Eurich, D. T., & Majumdar, S. R. (2006) · Diabetologia · doi:10.1007/s00125-006-0323-3 · Cited by 9
Wang, Z., & Arnold, J. C. (2024) · GeroScience · doi:10.1007/s11357-024-01162-8 · Cited by 10
Mata‐Cases, M., Franch‐Nadal, J., Mauricio, D., & Bolíbar, B. (2013) · Avances en Diabetología · doi:10.1016/j.avdiab.2013.09.002 · Cited by 8
Metformin and Other Biguanides: Pharmacology and Therapeutic Usage
Garber, A. J. (2004) · Wiley eBooks · doi:10.1002/0470862092.d0610 · Cited by 8
Rosas-Guzmán, J., & Lyra, R. (2010) · Revista de Endocrinología y Nutrición · Cited by 7
Metformina y diabetes mellitus tipo 2
Mata‐Cases, M. (2008) · Atención Primaria · doi:10.1157/13116631 · Cited by 7
Manejo práctico de antidiabéticos orales en pacientes con enfermedad renal
Pérez-Monteoliva, N. R. R., & Arroyo, R. A. (2006) · Nefrología · Cited by 7
Metformin and other biguanides: pharmacology and therapeutic usage
Samson, S. L., & Garber, A. J. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch43 · Cited by 7
Currie, C. J., & Holden, S. E. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12349 · Cited by 6
Παπάνας, Ν., Monastiriotis, C., Christakidis, D., & Maltezos, E. S. (2009) · Acta Clinica Belgica · doi:10.1179/acb.2009.008 · Cited by 6
Raccah, D. (2007) · Diabetologia · doi:10.1007/s00125-007-0630-3 · Cited by 6
Metformin Use Beyond Diabetes: Reducing Cardiovascular Events In The Healthy Elderly
Xu, D. (2020) · Gerontology & Geriatric Medicine · doi:10.24966/ggm-8662/100058 · Cited by 4
Oral hypoglycaemic drugs and newer agents use in Type 2 diabetes mellitus
Joshi, P., & Joshi, S. (2009) · South African Family Practice · doi:10.1080/20786204.2009.10873799 · Cited by 5
Wass, S. Y., Barnard, J. A., Kim, H. S., Sun, H., Telfer, W., Schilling, T., Barzilai, B., Bruemmer, D., Cho, L., Huang, J. C., et al. (2024) · Journal of Interventional Cardiac Electrophysiology · doi:10.1007/s10840-024-01955-z · Cited by 4
IMPACT OF DRUG EXPOSURE DEFINITIONS ON OBSERVED ASSOCIATIONS IN PHARMACOEPIDEMIOLOGY RESEARCH
Eskin, M., Simpson, S. H., & Eurich, D. T. (2018) · Journal of Population Therapeutics and Clinical Pharmacology · doi:10.22374/1710-6222.25.1.4 · Cited by 4
Metformin Associated Lactic Acidosis in Clinical Practice – A Case Series
Schädle, P., Tschritter, O., & Kellerer, M. (2020) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1149-9030 · Cited by 4
Bailey, C. J. (2013) · Springer eBooks · doi:10.1007/978-3-7091-1331-8_8 · Cited by 4
Nutrient regulation of inflammatory signalling in obesity and vascular disease
Palmer, T. M., & Salt, I. P. (2021) · Clinical Science · doi:10.1042/cs20190768 · Cited by 3
Weeda, E. R., Ward, R. C., Gebregziabher, M., Chandler, O., Strychalski, M. L., Axon, R. N., & Taber, D. J. (2023) · Primary care diabetes · doi:10.1016/j.pcd.2023.04.006 · Cited by 4
BARI 2D: A Reanalysis Focusing on Cardiovascular Events
GENUTH, S. M., Vlachos, H., Brooks, M. M., Bantle, J. P., CHAITMAN, B. R., Green, J., Kelsey, S. F., King, S. B., McBane, R. D., Sako, E. Y., et al. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.04.015 · Cited by 3
Suthar, S. D., Dholaria, N. K., Chavda, D. A., Chacko, J., Bhansali, N. B., Gosai, T. R., & Trivedi, H. R. (2014) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-014-0224-9 · Cited by 3
Miranda, V. P., Rodrigues, M., Rocha‐Gonçalves, F., & Nunes, J. P. L. (2009) · PubMed · Cited by 3
Tratamiento combinado de la diabetes mellitus tipo 2
Mata‐Cases, M. (2008) · FMC - Formación Médica Continuada en Atención Primaria · doi:10.1016/s1134-2072(08)70768-0 · Cited by 2
Is Rosiglitazone as Safe as BARI 2D and the Reanalysis of RECORD Imply?
DiNicolantonio, J. J., & Meier, P. (2013) · Cardiology · doi:10.1159/000356028 · Cited by 2
Chen, M., Lin, L.-Y., Hung, T., Lin, T., Li, C., Lin, T., Chen, Y., Liou, J., & Wang, M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70157 · Cited by 1
The ‘collateral benefits‘ of noninsulin therapies for Type 2 diabetes
Roe, E. D., PON, N. C., Hollander, P. A., & Raskin, P. (2013) · Diabetes Management · doi:10.2217/dmt.13.5 · Cited by 1
Modern antihyperglycemic therapy: safety and efficacy of glimepiride
Ruyatkina, L. A., & Юрьевич, С. М. (2012) · Diabetes Mellitus · doi:10.14341/2072-0351-5525 · Cited by 1
Androgen Therapy in Male Patients Suffering from Type 2 Diabetes: A Review of Benefits and Risks
Hassanabad, M. F., & Fatehi, M. (2018) · Current Diabetes Reviews · doi:10.2174/1573399814666180731125724 · Cited by 1
Regarder l’Evidence Based Medicine en face ? OUI, mais de plus près !
Grimaldi, A. (2010) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(10)70172-3 · Cited by 1
Sirois, C. (2006) · Pharmactuel
Александров, А. А., Kukharenko, S. S., & Ядрихинская, М. Н. (2010) · CyberLeninK (CyberLeninka)
Blake, E., & Sease, J. M. (2009) · Journal of Pharmacy Technology · doi:10.1177/875512250902500105
Insulin: standard therapy following oral hypoglycaemic failure in type 2 diabetes?
English, P. (2013) · British Journal of Hospital Medicine · doi:10.12968/hmed.2013.74.4.192
Oral hypoglycaemic drugs and newer agents use in TYPE 2 DIABETES
Joshi, P. (2008)
Kirkland, J. L., & Tchkonia, T. (2015) · Springer eBooks · doi:10.1007/978-3-319-23246-1_19
Глимепирид в современной гипогликемизирующей терапии: безопасность и эффективность
Ruyatkina, L. A., & Russian Federation (2012)
Gosmanova, E. O., Canada, R. B., Wan, J. Y., Mangold, T. A., & Wall, B. M. (2012) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e3182621dbf · Cited by 1
Update of the evidence-based guideline of the German Diabetes Association
Matthaei, S., Bierwirth, R., Fritsche, A., Häring, U., Kellerer, M., Kunt, T., Schernthaner, G., Siegel, E. G., & Thienel, F. (2008)
Abdelmoneim, A. (2015) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r30c4sw67
Eskin, M. (2017) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r30c4t003
Unlocking the Value: Communicating the Value of the Pharmacist to the Patient
Rege, S. V., & MacDonnell, C. P. (2019) · Journal of Media Literacy Education
Hong, J. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/4gbv-b042
Abbas, A., Kumar, N., Singh, S. K., Kumar, R., Ahmad, A., Nath, R., & Dixit, R. (2020) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20201185
Hypoglycemic therapy in patients with type 2 diabetes and chronic heart failure
Kakorin, S. V., Александровна, А. И., & Mkrtumyan, A. M. (2014) · Cardiosomatics · doi:10.26442/cs45071
Current literature in diabetes
(2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.619
Patterson, C., & Schisler, J. C. (2012) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.13480982.14859137
Aslanabadi, N., Beheshtirouy, S., Mashayekhi, S., Heidari, Z., Hamedani, S., & Entezari‐Maleki, T. (2022) · Pharmaceutical Sciences · doi:10.34172/ps.2022.10
(2006) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/01.med.0000235329.84906.3b
Soto, A., Iglesias, M. J., Buño, M., & Bellido, D. (2008) · Endocrinología y Nutrición · doi:10.1016/s1575-0922(08)76262-4
Metformin: Glycemic and Extra-Glycemic Actions
Massarini, S., & Luzi, L. (2025) · Springer eBooks · doi:10.1007/978-3-032-01700-0_10
Grycan, M., Zyśk, R., Grycan, G., Jakiel, G., Dudek, A., & Gromadzka, G. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177521
The effects of metformin on metabolism and cardiovascular disease in type 2 diabetes
de Jager, J. (2010) · Research Publications (Maastricht University) · doi:10.26481/dis.20100527jj
Metadata
- Authors
- Johnson, J. A., Simpson, S. H., Toth, E. L., & Majumdar, S. R.
- Affiliations
- University of Alberta (CA)
- Institute of Health Economics (CA)
- Corresponding author
- Johnson, J. A.
- Venue
- Diabetic Medicine
- Publisher
- Wiley
- Published
- 2005-03-21
- Volume
- 22
- Issue
- 4
- Pages
- 497-502
- ISSN
- 0742-3071 (ISSN-L)
- 1464-5491
- OpenAlex
- W1994294400
- Cited by
- 161
- References
- 31
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 5 · 2023: 4 · 2022: 6 · 2021: 6 · 2020: 6 · 2019: 7 · 2018: 7 · 2017: 8 · 2016: 6 · 2015: 11 · 2014: 11 · 2013: 11 · 2012: 11
- FWCI
- 6.42
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetic Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- metformin, type 2 diabetes, cardiovascular morbidity, cardiovascular mortality, macrovascular complications, cardiovascular hospitalization, oral antidiabetic drugs
- MeSH terms
- Aged, Aged, 80 and over, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Drug Therapy, Combination, Epidemiologic Methods, Female, Hospitalization, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Saskatchewan, Sulfonylurea Compounds
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
